Comparative Pharmacology
Head-to-head clinical analysis: DRONEDARONE HYDROCHLORIDE versus PRONESTYL SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRONEDARONE HYDROCHLORIDE versus PRONESTYL SR.
DRONEDARONE HYDROCHLORIDE vs PRONESTYL-SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dronedarone is a benzofuran derivative with antiarrhythmic properties belonging to class III. It blocks multiple ion channels (K+, Na+, Ca2+) and exhibits antiadrenergic effects. It prolongs atrial refractory periods and reduces ventricular rate.
Class Ia antiarrhythmic agent; blocks sodium channels, slowing phase 0 depolarization and decreasing myocardial excitability; also prolongs refractory period and has anticholinergic effects.
400 mg orally twice daily with meals.
500–1000 mg orally every 6 hours (sustained-release). Maximum 1.5 g per dose or 4 g per day.
None Documented
None Documented
Terminal half-life is approximately 24 hours (range 13–31 hours) after multiple dosing. Steady state is reached within 4–8 days. The prolonged half-life supports once-daily dosing but requires caution in renal impairment due to accumulation of inactive metabolites.
2.5-4.7 hours (procainamide); 6-9 hours (NAPA, active metabolite). Prolonged in renal impairment (up to 11-20 hours for procainamide, 30-42 hours for NAPA).
Approximately 6% of an oral dose is excreted unchanged in urine. The majority is eliminated as metabolites via biliary excretion into feces (84% of total radioactivity recovered in feces, 6% in urine).
Renal excretion: ~50-60% unchanged drug (procainamide), ~15-30% as N-acetylprocainamide (NAPA). Biliary/fecal: minor (<5%).
Category C
Category C
Antiarrhythmic
Antiarrhythmic